MRNA Drops 7.4% In A Day: How Does It Stack Against Peers?
Here is how Moderna (MRNA) stacks up against its peers in size, valuation, growth and margin.
- MRNA’s operating margin of -107.1% is negative, lowest among peers; PFE has 26.1%.
- MRNA’s revenue growth of -38.8% in the last 12 months is negative, lagging PFE, ALNY, SRPT, ABBV, AMGN.
- MRNA’s stock is down 66.3% in last 1 year, and trades at a PE of -3.1; it underperformed PFE, ALNY, ABBV, AMGN.
As a quick background, Moderna develops mRNA-based therapeutics and vaccines for infectious diseases, immuno-oncology, rare, cardiovascular, and auto-immune diseases, with 44 programs including 26 clinical trials across seven modalities.
| MRNA | PFE | ALNY | SRPT | ABBV | AMGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 9.1 | 135.7 | 60.4 | 1.7 | 386.0 | 148.7 |
| Revenue ($ Bil) | 3.1 | 63.8 | 2.3 | 2.5 | 58.3 | 34.9 |
| PE Ratio | -3.1 | 12.6 | -224.0 | -29.4 | 102.6 | 22.5 |
| LTM Revenue Growth | -38.8% | 13.5% | 17.2% | 64.9% | 6.1% | 12.9% |
| LTM Operating Margin | -107.1% | 26.1% | -4.9% | -0.0% | 23.5% | 23.5% |
| LTM FCF Margin | -114.6% | 19.5% | -3.2% | -18.3% | 31.3% | 30.4% |
| 12M Market Return | -66.3% | -12.4% | 78.0% | -86.1% | 16.6% | -13.5% |
Why does this matter? MRNA just went down -12.6% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell MRNA Stock to see if Moderna is really a falling knife. Sharp dips often come with rebound opportunities – see how the stock has dipped and recovered in the past through MRNA Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -38.8% | -52.6% | -64.2% | 6.4% |
| PFE | 13.5% | 6.8% | -41.1% | 24.5% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| SRPT | 64.9% | 53.0% | 33.3% | 32.9% |
| ABBV | 6.1% | 3.7% | -6.4% | 3.3% |
| AMGN | 12.9% | 18.6% | 7.1% | 1.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -107.1% | -123.3% | -62.8% | 49.9% |
| PFE | 26.1% | 23.5% | 7.4% | 37.7% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| SRPT | -0.0% | 11.5% | -21.5% | -57.5% |
| ABBV | 23.5% | 21.1% | 24.9% | 32.4% |
| AMGN | 23.5% | 21.7% | 28.0% | 36.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -3.1 | -4.5 | -8.1 | 8.5 |
| PFE | 12.6 | 18.7 | 76.7 | 9.2 |
| ALNY | -224.0 | -108.0 | -54.3 | -25.6 |
| SRPT | -29.4 | 55.8 | -16.6 | -16.1 |
| ABBV | 102.6 | 73.5 | 56.3 | 24.2 |
| AMGN | 22.5 | 34.2 | 22.9 | 21.6 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.